Chong-xian Pan

5.8k total citations · 2 hit papers
104 papers, 4.2k citations indexed

About

Chong-xian Pan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Chong-xian Pan has authored 104 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 38 papers in Molecular Biology. Recurrent topics in Chong-xian Pan's work include Bladder and Urothelial Cancer Treatments (35 papers), Prostate Cancer Treatment and Research (23 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Chong-xian Pan is often cited by papers focused on Bladder and Urothelial Cancer Treatments (35 papers), Prostate Cancer Treatment and Research (23 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Chong-xian Pan collaborates with scholars based in United States, China and Spain. Chong-xian Pan's co-authors include Wenru Song, Zheng Zhu, Lei Zheng, Hizra Farrukh, Zihai Li, Delong Liu, Veera Chandra Sekhar Reddy Chittepu, Kit S. Lam, Huihong Xu and Hongyong Zhang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Chong-xian Pan

103 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

2022 461 citations Hizra Farrukh, Veera Chandra Sekhar Reddy Chittepu et al. profile →
Combination strategies to maximize the benefits of cancer immunotherapy

2021 442 citations Shaoming Zhu, Tian Zhang et al. Journal of Hematology & Oncology profile →

Peers

Countries citing papers authored by Chong-xian Pan

Since Specialization

Citations

This map shows the geographic impact of Chong-xian Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chong-xian Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chong-xian Pan more than expected).

Fields of papers citing papers by Chong-xian Pan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chong-xian Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chong-xian Pan. The network helps show where Chong-xian Pan may publish in the future.

Co-authorship network of co-authors of Chong-xian Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Chong-xian Pan. A scholar is included among the top collaborators of Chong-xian Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chong-xian Pan. Chong-xian Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC). 2024 ·Journal of Clinical Oncology ·(unknown), Asmat Ullah, Rashmi Verma, Allen C. Gao, Primo N. Lara, Chong-xian Pan, Mamta Parikh	1
2	A transformable nanoplatform with multiple therapeutic and immunostimulatory properties for treatment of advanced cancers 2023 ·Biomaterials ·Xiangdong Xue, Haijing Qu, Ruonan Bo, Dalin Zhang, Zheng Zhu, Bai Xiang, (unknown), (unknown), Chong-xian Pan, Tzu‐yin Lin, Yuanpei Li	19
3	A phase II trial with copanlisib plus avelumab as maintenance therapy for metastatic bladder cancer after platinum-based chemotherapy. 2023 ·Journal of Clinical Oncology ·Hizra Farrukh, Zheng Zhu, Shaoming Zhu, Bruce Montgomery, Joshua J. Meeks, David James VanderWeele, (unknown), Robert Lew, Chong-xian Pan	2
4	Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer 2023 ·Scientific Reports ·(unknown), (unknown), Salma Siddiqui, Christopher A. Lucchesi, (unknown), Benjamin A. Mooso, Blythe Durbin‐Johnson, Ai‐Hong Ma, (unknown), Mamta Parikh, Maria Mudryj, Chong-xian Pan, P. Ghosh	7
5	Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques 2023 ·Cancer Cytopathology ·(unknown), Maria J. Troulis, Chong-xian Pan, Rema Rao	6
6	Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer 2022 ·Clinical Cancer Research ·Zheng Zhu, Ai‐Hong Ma, Hongyong Zhang, Tzu‐yin Lin, Xiangdong Xue, Hizra Farrukh, Shaoming Zhu, Wei Shi, Yuan Ruan, (unknown), Veera Chandra Sekhar Reddy Chittepu, (unknown), Yuanpei Li, Kit S. Lam, Chong-xian Pan	19
7	ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors 2022 ·JCI Insight ·Hasibur Rehman, Darshan S. Chandrashekar, (unknown), Saroj Nepal, Sai Akshaya Hodigere Balasubramanya, (unknown), (unknown), Ai‐Hong Ma, Ting Rao, Sumit Agarwal, Marie‐Lisa Eich, (unknown), Gurudatta Naik, Upender Manne, George J. Netto, C. Ryan Miller, Chong-xian Pan, Guru Sonpavde, Sooryanarayana Varambally, James E. Ferguson	40
8	Novel strategies for immuno-oncology breakthroughs with cell therapy 2021 ·Biomarker Research ·Hongtao Liu, Chong-xian Pan, Wenru Song, Delong Liu, Zihai Li, Lei Zheng	20
9	Combination strategies to maximize the benefits of cancer immunotherapy breakdown → 2021 ·Journal of Hematology & Oncology ·Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li, Chong-xian Pan	442
10	Novel Nanococktail of a Dual PI3K/mTOR Inhibitor and Cabazitaxel for Castration‐Resistant Prostate Cancer 2020 ·Advanced Therapeutics ·Yee Huang, Xiangdong Xue, Xiaocen Li, Bei Jia, Chong-xian Pan, Yuanpei Li, Tzu‐yin Lin	11
11	Self‐Assembled Nanoparticle‐Mediated Chemophototherapy Reverses the Drug Resistance of Bladder Cancers through Dual AKT/ERK Inhibition 2020 ·Advanced Therapeutics ·Weimin Yu, Xiangdong Xue, Ai‐Hong Ma, Yuan Ruan, Hongyong Zhang, Cheng Fan, Yuanpei Li, Chong-xian Pan, Tzu‐yin Lin	14
12	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy 2020 ·Journal of Hematology & Oncology ·Chong-xian Pan, Hongtao Liu, (unknown), Wenru Song, Delong Liu, Zihai Li, Lei Zheng	189
13	Fidelity of a PDX-CR model for bladder cancer 2019 ·Biochemical and Biophysical Research Communications ·Abdul M. Mondal, Ai-Hong Ma, Guangzhao Li, Ewa Krawczyk, Yuan Ruan, Lu Jie, Richard Schlegel, Lambros Stamatakis, Keith Kowalczyk, George Philips, Chong-xian Pan, Xuefeng Liu	16
14	Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia 2019 ·Nanomedicine Nanotechnology Biology and Medicine ·Tzu‐yin Lin, Yanjun Zhu, Yuanpei Li, Hongyong Zhang, Ai‐Hong Ma, Qilai Long, James Keck, Kit S. Lam, Chong-xian Pan, Brian A. Jonas	18
15	Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer 2017 ·Molecular Cancer Therapeutics ·Chengfei Liu, Cameron M. Armstrong, Wei Lou, Alan P. Lombard, Vito Cucchiara, (unknown), Joy C. Yang, Nagalakshmi Nadiminty, Chong-xian Pan, Christopher P. Evans, Allen C. Gao	54
16	The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer 2017 ·Clinical Cancer Research ·Shuxiong Zeng, Yanjun Zhu, Ai-Hong Ma, Weimin Yu, Hongyong Zhang, Tzu‐yin Lin, Wei Shi, Clifford G. Tepper, Paul T. Henderson, Susan Airhart, (unknown), (unknown), Ralph W. deVere White, Chong-xian Pan	44
17	Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer 2016 ·PLoS ONE ·(unknown), Hongyong Zhang, (unknown), Maike Zimmermann, Bin Hu, (unknown), Ruth L. Vinall, Tzu‐yin Lin, George D. Cimino, Patrick Chain, Momchilo Vuyisich, Cheryl D. Gleasner, Kim McMurry, Michael Malfatti, Kenneth W. Turteltaub, (unknown), Chong-xian Pan, (unknown)	13
18	Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors 2015 ·Clinical Cancer Research ·Benjamin Tomlinson, James A. Thomson, John S. Bomalaski, (unknown), (unknown), (unknown), Tianhong Li, (unknown), Karen Kelly, (unknown), Thomas J. Semrad, David R. Gandara, Chong-xian Pan, Primo N. Lara	66
19	Epidemiologic Trends in Renal Cell Carcinoma in the Cytokine and Post-Cytokine Eras: A Registry Analysis of 28,252 Patients 2012 ·Clinical Genitourinary Cancer ·(unknown), Benjamin Tomlinson, Monica Brown, Ann Brunson, Chong-xian Pan, Primo N. Lara	34
20	Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder 2004 ·Cancer ·Liang Cheng, Gregory T. MacLennan, Shaobo Zhang, Ming‐Sheng Wang, Chong-xian Pan, Michael O. Koch	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact